DECREASED CEREBROSPINAL-FLUID NITRATE LEVELS IN PARKINSONS-DISEASE, ALZHEIMERS-DISEASE AND MULTIPLE SYSTEM ATROPHY PATIENTS

被引:114
|
作者
KUIPER, MA
VISSER, JJ
BERGMANS, PLM
SCHELTENS, P
WOLTERS, EC
机构
[1] FREE UNIV AMSTERDAM HOSP,DEPT SURG,1081 HV AMSTERDAM,NETHERLANDS
[2] FREE UNIV AMSTERDAM HOSP,DEPT CLIN CHEM,1081 HV AMSTERDAM,NETHERLANDS
关键词
NITRIC OXIDE; NITRATE; NITRITE; PARKINSONS DISEASE; ALZHEIMERS DISEASE; MULTIPLE SYSTEM ATROPHY; CEREBROSPINAL FLUID; BIOPTERIN; NEURODEGENERATION;
D O I
10.1016/0022-510X(94)90155-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Nitric oxide (NO) is a recently discovered endogenous mediator of vasodilatation, neurotransmission, and macrophage cytotoxicity. NO is thought to have a function in memory and in long-term potentiation. At high concentrations NO is neurotoxic and may play a role in neurodegeneration. NO is formed from L-arginine by the enzyme NO synthase (NOS), for which tetrahydrobiopterin (BH4) is a necessary co-factor. Alzheimer's disease (AD) and, to a lesser degree, Parkinson's disease (PD) are thought to be associated with increased microglial activity, suggesting that NO production may be increased. Alternatively, in circumstances of reduced levels of intracellular L-arginine or BH4, NO production is diminished and neurotoxic oxygen radicals may be produced. Since BH4 is decreased in AD and PD brains, these diseases may be associated with decreased NO production. We investigated these two alternatives by measuring the NO degradation products nitrite and nitrate in cerebrospinal fluid (CSF) of PD (n = 103), AD (n = 13), and multiple system atrophy (MSA; n = 14) patients and controls (n = 20). We found for all patient groups, compared with controls, significantly decreased levels of nitrate, but not nitrite. This finding seems to indicate a decreased NO production of the central nervous system (CNS) in these neurodegenerative disorders.
引用
收藏
页码:46 / 49
页数:4
相关论文
共 50 条
  • [41] OLFACTORY DYSFUNCTION IN ALZHEIMERS-DISEASE AND PARKINSONS-DISEASE
    SERBY, M
    CORWIN, J
    CONRAD, P
    ROTROSEN, J
    AMERICAN JOURNAL OF PSYCHIATRY, 1985, 142 (06): : 781 - 782
  • [42] DEMENTIA OF PARKINSONS-DISEASE AND ALZHEIMERS-DISEASE - IS THERE A DIFFERENCE
    STERN, MB
    GUR, RC
    SAYKIN, AJ
    HURTIG, HI
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1986, 34 (06) : 475 - 478
  • [43] ALZHEIMERS-DISEASE AND PARKINSONS-DISEASE - NEUROPSYCHOLOGICAL DIFFERENTIATION
    LAVERNHE, G
    POLLAK, P
    BRENIER, F
    GAIO, JM
    HOMMEL, M
    PELLAT, J
    PERRET, J
    REVUE NEUROLOGIQUE, 1989, 145 (01) : 24 - 30
  • [45] CHOLINERGIC MARKERS IN ALZHEIMERS-DISEASE AND PARKINSONS-DISEASE
    LANGE, KW
    ROSSOR, MN
    JENNER, P
    MARSDEN, CD
    NEUROBIOLOGY OF AGING, 1990, 11 (03) : 273 - 274
  • [46] TACRINE TREATMENT MODIFIES CEREBROSPINAL-FLUID NEUROPEPTIDE LEVELS IN ALZHEIMERS-DISEASE
    MINTHON, L
    EDVINSSON, L
    GUSTAFSON, L
    DEMENTIA, 1994, 5 (06): : 295 - 301
  • [47] RAISED CEREBROSPINAL-FLUID COPPER CONCENTRATION IN PARKINSONS-DISEASE
    PALL, HS
    BLAKE, DR
    GUTTERIDGE, JM
    WILLIAMS, AC
    LUNEC, J
    HALL, M
    TAYLOR, A
    LANCET, 1987, 2 (8553): : 238 - 241
  • [48] INCREASED CEREBROSPINAL-FLUID CONCENTRATION OF NITRITE IN PARKINSONS-DISEASE
    OURESHI, GA
    BAIG, S
    BEDNAR, I
    SODERSTEN, P
    FORSBERG, G
    SIDEN, A
    NEUROREPORT, 1995, 6 (12) : 1642 - 1644
  • [49] CEREBROSPINAL-FLUID NEUROCHEMISTRY IN THE MYOCLONIC SUBTYPE OF ALZHEIMERS-DISEASE
    KAYE, JA
    MAY, C
    ATACK, JR
    DALY, E
    SWEENEY, DL
    BEAL, MF
    KAUFMAN, S
    MILSTIEN, S
    FRIEDLAND, RP
    RAPOPORT, SI
    ANNALS OF NEUROLOGY, 1988, 24 (05) : 647 - 650
  • [50] CEREBROSPINAL-FLUID NEUROPEPTIDES IN ALZHEIMERS-DISEASE AND VASCULAR DEMENTIA
    HEILIG, M
    SJOGREN, M
    BLENNOW, K
    EKMAN, R
    WALLIN, A
    BIOLOGICAL PSYCHIATRY, 1995, 38 (04) : 210 - 216